To read the full story, subscribe or sign in.

AstraZeneca Buying CAT, Giving Valuation Of $1.3B

Last updated: Oct. 19, 2019

LONDON - AstraZeneca plc is buying Cambridge Antibody Technology (CAT) Group plc, the UK's largest biotech, in an agreed cash deal that will cost AstraZeneca £567 million, and values CAT at £702 million (US$1.3 billion). (BioWorld Today)

BioWorld

Accuracy, utility of COVID-19 lateral flow tests questioned in the U.K.

BioWorld MedTech

LONDON – A huge row has broken out in the U.K. about the accuracy and utility of COVID-19 lateral flow tests (LFT) in screening asymptomatic people, as a pilot...

Israel continues to shine as hub of med-tech innovation

BioWorld MedTech

In recent years, Israel has proven to be a hot spot for med-tech innovation. The country boasts more than 1,500 companies in the health care and life sciences...

Today's news in brief

BioWorld

BioWorld briefs for Jan. 22.

Sinovac’s COVID-19 vaccine more than 78% effective in Brazil trials

BioWorld

CAJICA, Colombia – Brazil's Butantan Institute and the government of the state of Sao Paulo released efficacy results on Jan. 7 for Coronavac, developed by...

Sarepta DMD phase II hangs in ‘balance’ as disparity in North Star leads astray

BioWorld

Sarepta Therapeutics Inc.’s miss on a key phase II ambulatory endpoint in its Duchenne muscular dystrophy (DMD) trial may have been caused by a dramatic disparity...